Maastricht University (FEMCHIP)
FEMCHIP received NWO Perspectief Grant
Endometriosis (10% of women) and adenomyosis (30% of women) are conditions in which the womb lining grows in places where it should not, causing pain and infertility. Even though millions of women suffer from these diseases, they remain poorly understood, hard to diagnose, and treatment options are very limited. This has major negative impacts on patients’ lives, as well as the Dutch healthcare system and economy. The NWO Perspectief project FEMCHIP aims to improve diagnosis by developing new imaging methods, perform in-depth characterization of the diseased tissues, build advanced 3D models of endometriosis and adenomyosis to increase understanding, and use these models to search for treatments to reduce pain and improve fertility.
NWO Perspectief
The NWO Perspectief programme is a major Dutch research funding initiative designed to accelerate technological innovation through large-scale, public-private research collaborations. It stimulates multidisciplinary consortia of universities, companies, and societal organisations to jointly develop new technologies that address societal challenges and create economic and social impact in the Netherlands. By supporting research that bridges fundamental science and application, Perspectief aims to solve innovation bottlenecks, strengthen the Dutch knowledge and innovation system, and contribute to national innovation agendas. Projects are selected based on excellent scientific quality, technological development, and potential societal impact, and typically span several years with NWO funding contributions between 2 and 5 million euros.
The FEMCHIP consortium is a collaboration between Maastricht University, Maastricht UMC+, UMC Utrecht, Amsterdam UMC and Radboud University. To address the urgent need for better diagnostics and treatments, FEMCHIP collaborates closely with Dutch and international industry partners, patient organisations, and innovation hubs to accelerate solutions for these undeserved diseases.
Support from Hezelburcht
Hezelburcht’s specialists are proud to have supported the FEMCHIP consortium during the writing process of the full proposal and strategic advice. We wish the entire consortium success with the continuation of the project!
This funding gives FEMCHIP the opportunity to make meaningful progress in understanding and diagnosing endometriosis and adenomyosis. We’re pleased to have had support from the Hezelburcht team in developing a strong and realistic proposal. - Prof Dr R.K. Truckenmüller, Maastricht University
